Nothing Special   »   [go: up one dir, main page]

WO2002092765A3 - Novel telomerase inhibitors and uses therefor - Google Patents

Novel telomerase inhibitors and uses therefor Download PDF

Info

Publication number
WO2002092765A3
WO2002092765A3 PCT/US2002/014927 US0214927W WO02092765A3 WO 2002092765 A3 WO2002092765 A3 WO 2002092765A3 US 0214927 W US0214927 W US 0214927W WO 02092765 A3 WO02092765 A3 WO 02092765A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
uses therefor
telomerase inhibitors
pin2
novel telomerase
Prior art date
Application number
PCT/US2002/014927
Other languages
French (fr)
Other versions
WO2002092765A2 (en
Inventor
Kun Ping Lu
Xiao Zhen Zhou
Original Assignee
Beth Israel Hospital
Kun Ping Lu
Xiao Zhen Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Kun Ping Lu, Xiao Zhen Zhou filed Critical Beth Israel Hospital
Priority to AU2002303712A priority Critical patent/AU2002303712A1/en
Publication of WO2002092765A2 publication Critical patent/WO2002092765A2/en
Priority to US10/705,531 priority patent/US20040142357A1/en
Publication of WO2002092765A3 publication Critical patent/WO2002092765A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides molecules including Pin2 and telomerase binding polypeptides, polynucleotides encoding such polypeptides, and antibodies specifically immunoreactive to said polypeptides. The invention also provides methods for screening agents which modulate the function or expression of said Pin2 and telomerase binding polypeptides. Methods are provided for disease diagnosis and treatment using said agents, said antibodies and oligonucleotides derived from the above polynucleotides.
PCT/US2002/014927 2001-05-11 2002-05-10 Novel telomerase inhibitors and uses therefor WO2002092765A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002303712A AU2002303712A1 (en) 2001-05-11 2002-05-10 Novel telomerase inhibitors and uses therefor
US10/705,531 US20040142357A1 (en) 2001-05-11 2003-11-10 Novel telomerase inhibitors and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29036301P 2001-05-11 2001-05-11
US60/290,363 2001-05-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/705,531 Continuation US20040142357A1 (en) 2001-05-11 2003-11-10 Novel telomerase inhibitors and uses therefor

Publications (2)

Publication Number Publication Date
WO2002092765A2 WO2002092765A2 (en) 2002-11-21
WO2002092765A3 true WO2002092765A3 (en) 2004-01-08

Family

ID=23115650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/014927 WO2002092765A2 (en) 2001-05-11 2002-05-10 Novel telomerase inhibitors and uses therefor

Country Status (3)

Country Link
US (1) US20040142357A1 (en)
AU (1) AU2002303712A1 (en)
WO (1) WO2002092765A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940977B1 (en) * 2009-01-13 2016-11-18 Oreal USE OF COMPLEX FORMS OF THE CALMODULIN-LIKE SKIN PROTEIN CLSP PROTEIN
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
CN102311493B (en) * 2010-07-02 2014-06-04 中国科学院上海生命科学研究院 Peptide inhibiting telomerase activity, its preparation method and application
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2012162698A1 (en) 2011-05-26 2012-11-29 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of immune disorders
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
US9968579B2 (en) 2014-07-17 2018-05-15 Beth Isreal Deaconess Medical Center, Inc. ATRA for modulating Pin1 activity and stability
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
CN111978389A (en) * 2020-07-17 2020-11-24 湖州师范学院 Active fragment for efficiently inhibiting telomerase, fusion protein thereof, preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIAO ET AL.: "Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human heptacellular carcinoma", HEPATOLOGY, vol. 32, 2000, pages 721 - 727, XP002965346 *
ZHOU ET AL.: "The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor", CELL, vol. 107, 2 November 2001 (2001-11-02), pages 347 - 359, XP002965347 *

Also Published As

Publication number Publication date
US20040142357A1 (en) 2004-07-22
WO2002092765A2 (en) 2002-11-21
AU2002303712A1 (en) 2002-11-25

Similar Documents

Publication Publication Date Title
WO2004074455A3 (en) Fc REGION VARIANTS
DK1434791T3 (en) Specific binding agents for human angiopoietin-2
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
EP2154157A3 (en) FC region variants
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2002065134A3 (en) Modulators of p53-p300 interactions and screening methods therefor
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
WO2004113500A3 (en) B7s1: an immune modulator
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
WO2002072751A3 (en) Polynucleotides encoding a metalloprotease, mp-1
WO2004076614A3 (en) Human nucleic acid sequences obtained from prostatic carcinomas
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2004090103A8 (en) Identification of novel nogo-receptors and methods related thereto
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
WO2002053719A3 (en) Cytoskeleton-associated proteins
WO2000076552A8 (en) Methods and compositions for control of bone formation via modulation of leptin activity
WO2002070563A3 (en) Nuclear hormone receptor ligand binding domain
WO2000052161A3 (en) Leukocyte- and blood-associated proteins
WO2002072612A3 (en) Peptidic modulators of the androgen receptor
WO2003025197A3 (en) Mutant sh3-binding protein compositions and methods
IL155687A0 (en) Polynucleotides encoding hlrrsi1 polypeptides
WO2003059374A3 (en) Use of dimer-specific nuclear localisation signal peptides (dsnls) derived from the stat dna binding domain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10705531

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP